Received Apr 10, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y012921 | — |
no additional AE; re vaccinated on 15/Nov/2025; Administration of a "GARDASIL" that had experienced a temperature excursion; This spontaneous report was received from a nurse, concerning a 16-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 08-Oct-2025, a temperature excursion (TE) occurred for 1000 time (units not provided), minimum temperature -2° and maximum 8.59, when discovered (17-Oct-2025) 3.55° for Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9). On 15-Oct-2025, the patient vaccinated with a vaccine involved in the TE, as the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (lot #Y012921 has been verified to be valid, expiration date reported and confirmed as 08-Jan-2027), by Intramuscular route (douse not provided), as prophylaxis. ((Product storage error). On 05-Nov-2025, the patient was revaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (dose, route, lot # and expiration date were not reported). (Extra dose administered). No additional adverse event reported (No adverse event). This is one of several reports received from the same reporter.